

RESULT 1

AAM40223

ID AAM40223 standard; Protein; 229 AA.

XX

AC AAM40223;

XX

DT 22-OCT-2001 (first entry)

XX

DE Human polypeptide SEQ ID NO 3368.

XX

KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.

XX

OS Homo sapiens.

XX

PN WO200153312-A1.

XX

FD 26-JUL-2001.

XX

PF 26-DEC-2000; 2000WO-US34263.

XX

PR 21-JAN-2000; 2000US-0488725.

PR 25-APR-2000; 2000US-0552317.

PR 09-JUL-2000; 2000US-0598042.

PR 19-JUL-2000; 2000US-0620312.

PR 03-AUG-2000; 2000US-0653450.

PR 14-SEP-2000; 2000US-0662191.

PR 19-OCT-2000; 2000US-0693036.

PR 29-NOV-2000; 2000US-0727344.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;

PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;

PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;

XX

DR WPI; 2001-442253/47.

DR N-PSDB; AAI59379.

XX

PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -

XX

PS Example 5; SEQ ID NO 3368; 10078pp; English.

XX

CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.

XX

SQ Sequence 229 AA;

Query Match 100.0%; Score 1198; DB 22; Length 229;

Best Local Similarity 100.0%; Pred. No. 2.5e-127;

Matches 229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MAAQPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEDWTQVVKGSSPLGPAGLGAEPP	60
Db	1	MAAQPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMEDWTQVVKGSSPLGPAGLGAEPP	60
Qy	61	AAGPOLPSWLQPERCAVFOCAQCHAVLADSVHLAWDLRSRLGAVVFSRVTNVNVLEAPFL	120
Db	61	AAGPOLPSWLQPERCAVFOCAQCHAVLADSVHLAWDLRSRLGAVVFSRVTNVNVLEAPFL	120
Qy	121	VGIEGSLKGSTYNLLFCGSCGIPVGFHLYSTHAALAALRGHFCLSSDKMVCYLLKTKAIV	180
Db	121	VGIEGSLKGSTYNLLFCGSCGIPVGFHLYSTHAALAALRGHFCLSSDKMVCYLLKTKAIV	180
Qy	181	NASEMDIQNVPLSEKIAELKEKIVLTHNRLKSLMKILSEVTPDQSKPEN	229
Db	181	NASEMDIQNVPLSEKIAELKEKIVLTHNRLKSLMKILSEVTPDQSKPEN	229

XX	Sequence	231 AA;
XX	Seq	
XX	Query Match	100.0%; Score 1198; DB 22; Length 231;
XX	Best Local Similarity	100.0%; Pred. No. 2.5e-127;
XX	Matches	229; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1	MAAOPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMENDTOVVKSSPLGPAIGAEAP 60
DB	3	MAAOPLRHRSRCATPPRGDFCGGTERAIDQASFTTSMENDTOVVKSSPLGPAIGAEAP 62
QY	61	AAGPOLPSWLOPERCAVRCQAQCAVLADSVHLANDLSRSGAVVPSRVYNNVLEAPPL 120
DB	63	AAGPOLPSWLOPERCAVRCQAQCEAVLADSVHLANDLSRSLGAVVPSRVYNNVLEAPPL 122
QY	121	VGIEGSLKSGTYNLLFCGSCGIPVGFPHLYSTHAAALALRGHCTSSDRKVCYLKTKAIV 180
DB	123	VGIEGSLKSGTYNLLFCGSCGIPVGFPHLYSTHAAALALRGHCTSSDRKVCYLKTKAIV 182
QY	181	NASEMDIQNVPLSEKIAELKEKIVLTNRNLKSIKILSEVTPDQSKPEN 229
DB	183	NASEMDIQNVPLSEKIAELKEKIVLTNRNLKSIKILSEVTPDQSKPEN 231

RESULT 3
 AAM42009
 ID AAM42009 standard; Protein; 231 AA.
 AC AAM42009;
 CX 22-OCT-2001 (first entry)
 CX Human polypeptide SEQ ID NO 6940.
 CX Human; nocrotropic; immunosuppressant; cytostatic; gene therapy; cancer;
 CX peripheral nervous system; neuropathy; central nervous system; CNS;
 CX Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 CX amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 CX chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 CX leukaemia.
 CX Homo sapiens.
 CX MO200153312-A1.
 CX 26-JUL-2001.
 CX 26-DEC-2000; 2000WO-US34263.
 CX 21-JAN-2000; 2000US-0488725.
 CX 25-APR-2000; 2000US-0552317.
 CX 09-JUL-2000; 2000US-0598042.
 CX 19-JUL-2000; 2000US-0620312.
 CX 03-AUG-2000; 2000US-0653450.
 CX 14-SEP-2000; 2000US-0662191.
 CX 19-OCT-2000; 2000US-0693036.
 CX 29-NOV-2000; 2000US-0727344.
 CX (HYSE-) HYSEQ INC.
 CX Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 CX Wang J, Wang Z, Wenman T, Xu C, Xue AU, Yang Y, Zhang J;
 CX Zhao QH, Zhou P, Goodrich R, Drmanac RT;
 CX WPI; 2001-442253/47.
 CX N-PSDB; AAI61165.
 CX Novel nucleic acids and polypeptides, useful for treating disorders
 CX PT such as central nervous system injuries -
 CX Example 2; SEQ ID NO 6940; 10078bp; English.
 CX The invention relates to human nucleic acids (AA157798-AA161369) and
 CX the encoded polypeptides (AAM38642-AAM4213) with nocrotropic;
 CX immunosuppressant and cytostatic activity. The polynucleotides are useful
 CX in gene therapy. A composition containing a polypeptide or polynucleotide
 CX of the invention may be used to treat diseases of the peripheral nervous
 CX system, such as peripheral nervous injuries, peripheral neuropathy and
 CX localised neuropathies and central nervous system diseases, such as
 CX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CX utilisation of the activities such as: Immune system suppression,
 CX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CX assays for receptor activity, arthritis and inflammation, leukaemias and
 CX C.N.S disorders.
 CX Note: The sequence data for this patent did not form part of the printed
 CX specification.